LENZ Therapeutics, Inc. Common Stock (LENZ) Stock
Key stats
- Market cap
- $129.14M
- Price / Earnings ratio
- -0.9x
- EPS (TTM)
- -$4.53
- Volume
- Loading
- 52-week high
- $32.13
- 52-week low
- $2.80
Source: third-party data provider, as of November 13, 2026
Compare with LENZ
Recent news

LENZ Therapeutics Q3 Earnings Call Highlights
LENZ Therapeutics Q3 Earnings Call Highlights
LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ

LENZ Therapeutics Q2 Earnings Call Highlights
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.18
- MACD 12/26/9
- 0.04
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.15
- SMA 50
- $3.87
- Price above SMA 50
- EMA 50
- $3.90
- Price above EMA 50
- SMA 200
- $7.38
- Price below SMA 200
- EMA 200
- $8.68
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

LENZ Therapeutics Q3 Earnings Call Highlights
LENZ Therapeutics Q3 Earnings Call Highlights
LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ

LENZ Therapeutics Q2 Earnings Call Highlights
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ

Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ

LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ

LENZ Therapeutics Q1 Earnings Call Highlights
LENZ Therapeutics Q1 Earnings Call Highlights
LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ

Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
LENZ

Why Lenz Therapeutics Stock Crashed Today
Why Lenz Therapeutics Stock Crashed Today
LENZ
News tone: automated (AI) classification of the article's content, not a price prediction.
About LENZ Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director | 1972 |
| Mr. Daniel R. Chevallard CPA | Chief Financial Officer | 1980 |
| Mr. James W. McCollum | Co-Founder & Director | 1955 |
| Mr. Shawn Olsson | Chief Commercial Officer | 1983 |
| Mr. Marc G. Odrich M.D. | Chief Medical Officer | 1959 |
| Mr. Domenick Porfidia | Vice President of Sales | — |
| Mr. David Choromanski | Vice President of Marketing | — |
| Ms. Melissa Rosness | Senior Vice President of Manufacturing Operations | — |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 59.18
- MACD 12/26/9
- 0.04
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.15
- SMA 50
- $3.87
- Price above SMA 50
- EMA 50
- $3.90
- Price above EMA 50
- SMA 200
- $7.38
- Price below SMA 200
- EMA 200
- $8.68
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $18.75
- High
- $45.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +37.8 | -24.5 | -3.3 | +14.7 | +40.4 | -5.0 | +4.5 | +18.2 | +27.5 | -22.7 | ||
| 2025 | -9.8 | -14.0 | +19.4 | +9.7 | +1.1 | +0.5 | -0.9 | +28.9 | +18.7 | -39.4 | +9.3 | -47.4 |
| 2026 | -1.1 | -17.2 | -33.1 | -4.0 | -12.4 | -23.7 | -8.5 | +4.2 | -26.6 | -19.5 | +34.8 |



